TY - JOUR
AU - G. Bereda
A1 - 
AB - BACKGROUND: Bipolar disorder (BD) is a chronic psychiatric condition that requires careful pharmacological management. Ensuring treatment effectiveness, safety, adherence, and proper monitoring is essential, especially in pediatric, pregnant, and cognitively impaired patients. OBJECTIVE: To review the available evidence on treatment outcomes, safety, adherence, and monitoring in bipolar disorder. METHODS: A literature search was conducted using PubMed, Scopus, Web of Science, and Google Scholar. A comprehensive review of systematic reviews, meta-analyses, cohort studies, clinical trials, and case reports was performed. This review was guided by the Scale for the Assessment of Narrative Review Articles (SANRA) criteria. The findings were synthesized qualitatively. RESULTS: This review highlights important challenges and therapeutic considerations in bipolar disorder management. Medication adherence and laboratory monitoring compliance were generally poor. Sleep disturbances were associated with poorer functional outcomes. Combination therapy reduced the risk of manic and depressive recurrence but may lower overall functioning in some patients. Lithium showed favorable long-term outcomes, including reduced sickness absence and lower mortality, whereas pregabalin was linked to poorer occupational outcomes. Untreated bipolar disorder during pregnancy was associated with prematurity and low birth weight. Mechanistically, lithium, valproate, and emerging agents may modulate neuroplasticity and intracellular signaling pathways; however, evidence for cognitive improvement remains limited and inconsistent. CONCLUSION: Lithium and combination therapies improve relapse prevention, cognitive outcomes, and mortality. However, adverse effects and poor adherence remain challenges. Individualized strategies, regular monitoring, and tailored interventions are essential to optimize care.
AD - Department of Pharmacy, Marie Stopes International Ethiopia (MSIE), Ambo, Ethiopia.
AN - 42324130
BT - Neuropsychopharmacol Rep
C5 - Opioids & Substance Use
CP - 2
DA - 06/2026
DO - 10.1002/npr2.70141
DP - NLM
IS - 2
JF - Neuropsychopharmacol Rep
LA - eng
N2 - BACKGROUND: Bipolar disorder (BD) is a chronic psychiatric condition that requires careful pharmacological management. Ensuring treatment effectiveness, safety, adherence, and proper monitoring is essential, especially in pediatric, pregnant, and cognitively impaired patients. OBJECTIVE: To review the available evidence on treatment outcomes, safety, adherence, and monitoring in bipolar disorder. METHODS: A literature search was conducted using PubMed, Scopus, Web of Science, and Google Scholar. A comprehensive review of systematic reviews, meta-analyses, cohort studies, clinical trials, and case reports was performed. This review was guided by the Scale for the Assessment of Narrative Review Articles (SANRA) criteria. The findings were synthesized qualitatively. RESULTS: This review highlights important challenges and therapeutic considerations in bipolar disorder management. Medication adherence and laboratory monitoring compliance were generally poor. Sleep disturbances were associated with poorer functional outcomes. Combination therapy reduced the risk of manic and depressive recurrence but may lower overall functioning in some patients. Lithium showed favorable long-term outcomes, including reduced sickness absence and lower mortality, whereas pregabalin was linked to poorer occupational outcomes. Untreated bipolar disorder during pregnancy was associated with prematurity and low birth weight. Mechanistically, lithium, valproate, and emerging agents may modulate neuroplasticity and intracellular signaling pathways; however, evidence for cognitive improvement remains limited and inconsistent. CONCLUSION: Lithium and combination therapies improve relapse prevention, cognitive outcomes, and mortality. However, adverse effects and poor adherence remain challenges. Individualized strategies, regular monitoring, and tailored interventions are essential to optimize care.
PY - 2026
SN - 2574-173x
SP - e70141
ST - Pharmacological Management, Safety, and Outcomes in Bipolar Disorder: An Integrated Narrative Review of Clinical and Translational Evidence
T1 - Pharmacological Management, Safety, and Outcomes in Bipolar Disorder: An Integrated Narrative Review of Clinical and Translational Evidence
T2 - Neuropsychopharmacol Rep
TI - Pharmacological Management, Safety, and Outcomes in Bipolar Disorder: An Integrated Narrative Review of Clinical and Translational Evidence
U1 - Opioids & Substance Use
U3 - 10.1002/npr2.70141
VL - 46
VO - 2574-173x
Y1 - 2026
ER -